Acadia Pharmaceuticals (ACAD) Share-based Compensation (2010 - 2026)

Acadia Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 29.16% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $55.5 million (down 12.92% YoY), while the FY2025 annual figure was $52.1 million, down 22.24% from the prior year.
• Share-based Compensation was $14.7 million for Q1 2026 at Acadia Pharmaceuticals, up from $13.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $26.2 million in Q3 2024 to a low of $10.4 million in Q4 2024.
• Historically, Share-based Compensation has averaged $15.8 million across 5 years, with a median of $14.8 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 41.13% in 2024, then slumped 49.63% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $14.4 million in 2022, then gained by 25.04% to $18.0 million in 2023, then plunged by 42.02% to $10.4 million in 2024, then climbed by 26.65% to $13.2 million in 2025, then climbed by 11.05% to $14.7 million in 2026.
• The last three Share-based Compensation figures came in at $14.7 million (Q1 2026), $13.2 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.